Siak Pui Yan, Khoo Alan Soo-Beng, Leong Chee Onn, Hoh Boon-Peng, Cheah Shiau-Chuen
Faculty of Medicine and Health Sciences, UCSI University, Kuala Lumpur 56000, Malaysia.
Cancer Research Centre, Molecular Pathology Unit, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam 40170, Selangor, Malaysia.
Cancers (Basel). 2021 Jul 12;13(14):3490. doi: 10.3390/cancers13143490.
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy that shows a remarkable ethnic and geographical distribution. It is one of the major public health problems in some countries, especially Southern China and Southeast Asia, but rare in most Western countries. Multifactorial interactions such as Epstein-Barr virus infection, individual's genetic susceptibility, as well as environmental and dietary factors may facilitate the pathogenesis of this malignancy. Late presentation and the complex nature of the disease have led it to become a major cause of mortality. Therefore, an effective, sensitive, and specific molecular biomarker is urgently needed for early disease diagnosis, prognosis, and prediction of metastasis and recurrence after treatment. In this review, we discuss the recent research status of potential biomarker discovery and the problems that need to be explored further for better NPC management. By studying the aberrant pattern of these candidate biomarkers that promote NPC development and progression, we are able to understand the complexity of this malignancy better, hence positing our stands better towards strategies that may provide a way forward to the discovery of more reliable and specific biomarkers for diagnosis and targeted therapeutic development.
鼻咽癌(NPC)是一种上皮性恶性肿瘤,具有显著的种族和地域分布特征。它是一些国家,尤其是中国南方和东南亚地区的主要公共卫生问题之一,但在大多数西方国家较为罕见。多种因素相互作用,如爱泼斯坦-巴尔病毒感染、个体遗传易感性以及环境和饮食因素等,可能促进这种恶性肿瘤的发病机制。疾病发现较晚以及其复杂的性质使其成为主要的死亡原因。因此,迫切需要一种有效、敏感且特异的分子生物标志物用于疾病的早期诊断、预后评估以及治疗后转移和复发的预测。在本综述中,我们讨论了潜在生物标志物发现的最新研究现状以及为更好地管理鼻咽癌需要进一步探索的问题。通过研究这些促进鼻咽癌发生和发展的候选生物标志物的异常模式,我们能够更好地理解这种恶性肿瘤的复杂性,从而更好地支持那些可能为发现更可靠、特异的诊断生物标志物和靶向治疗发展提供途径的策略。